Rosa Priscila, Santos Juliana Dos, Lehmen Tássia Fontana, Weber Julia, Flores Fernanda Cramer, Silva Cristiane de Bona da, Oliveira Sara Marchesan, Brusco Indiara, Milani Géssica Brum, Adams Andréa Inês Horn
a Programa de Pós-Graduação em Ciências Farmacêuticas.
b Departamento de Farmácia Industrial.
Drug Dev Ind Pharm. 2016 Jan;42(1):19-27. doi: 10.3109/03639045.2015.1022554. Epub 2015 Mar 16.
Our group previously reported the photoinstability of some desonide topical commercial formulations under direct exposure to UVA radiation.
This study aimed to prepare and characterize a gel-cream containing desonide, with greater photostability than the commercial gel-cream (C-GC). Benzophenone-3 (BP-3) was used as a photostabilizing agent.
The gel-cream developed (D-GC) containing BP-3 at 0.1% was prepared and characterized regarding its pH, drug content, spreadability, viscosity, in vitro drug release and in vitro permeation. The in vivo anti-inflammatory effect was assessed by ear edema measurement, croton oil-induced acute skin inflammation and myeloperoxidase assay.
D-GC presented characteristics compatible with topical application, appropriate drug content and good spreadability, and non-Newtonian behavior with pseudoplastic flow. D-GC showed a good photostability profile, presenting a desonide content of 95.70% after 48 h of exposure to UVA radiation, and stability under room conditions during 60 days. The amount of desonide released from D-GC and C-GC was 57.8 and 51.7 µg/cm, respectively, measured using the vertical Franz cell. The in vitro skin permeation showed that desonide reached the site of action of the topical corticosteroids, from both formulations; however, the desonide amount retained in the dermis was lower with D-GC. The in vivo evaluation of topical anti-inflammatory activity indicated that D-GC presented the same biological effect as C-GC.
D-GC represents a promising approach to treat dermatological disorders, since it presented satisfactory physicochemical characteristics, the same biological activity as C-GC and superior photostability, conferred by the addition of BP-3 at 0.1%.
我们的研究小组之前报道了一些地索奈德局部用市售制剂在直接暴露于UVA辐射下的光不稳定性。
本研究旨在制备并表征一种含地索奈德的凝胶乳膏,其光稳定性高于市售凝胶乳膏(C-GC)。二苯甲酮-3(BP-3)用作光稳定剂。
制备含0.1%BP-3的凝胶乳膏(D-GC),并对其pH值、药物含量、铺展性、粘度、体外药物释放和体外渗透进行表征。通过耳部水肿测量、巴豆油诱导的急性皮肤炎症和髓过氧化物酶测定评估体内抗炎作用。
D-GC呈现出与局部应用相匹配的特性、合适的药物含量和良好的铺展性,具有假塑性流动的非牛顿行为。D-GC显示出良好的光稳定性,在暴露于UVA辐射48小时后地索奈德含量为95.70%,在室温条件下60天内保持稳定。使用垂直Franz扩散池测得,D-GC和C-GC释放的地索奈德量分别为57.8和51.7μg/cm。体外皮肤渗透表明,两种制剂中的地索奈德均到达局部皮质类固醇的作用部位;然而,D-GC保留在真皮中的地索奈德量较低。局部抗炎活性的体内评价表明,D-GC与C-GC具有相同的生物学效应。
D-GC是一种治疗皮肤病的有前景的方法,因为它具有令人满意的理化特性,与C-GC具有相同的生物活性,并且通过添加0.1%的BP-3具有优异的光稳定性。